Prediction of cardiovascular events in patients with chronic myeloid leukaemia using baseline risk factors and coronary artery calcium scoring

Abstract

A standardised method for cardiovascular risk stratification in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors is lacking. We report an algorithm for risk stratification applicable to all patients commencing tyrosine kinase inhibitor therapy based on age, prior cardiovascular disease and Framingham Risk Score, incorporating coronary artery calcium scoring in patients at intermediate Framingham Risk Score risk. Of 88 patients retrospectively studied, major adverse cardiovascular event rates in our study‐defined low‐, intermediate‐ and high‐risk categories were 0%, 10% and 19% respectively. Of nine patients down‐classified from intermediate to low risk on the basis of coronary artery calcium scoring, none went on to experience a major adverse cardiovascular event.

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes

“… 39 , 96 Risk of CVEs on treatment appears lower in patients with minimal or no pretreatment risk factors; risk of on-treatment events increases with the number of baseline cardiovascular risk factors. 97 It is estimated, however, that 30% of patients with CML have baseline cardiovascular risk factors such as hypertension and obesity, with more than 10% having diabetes. 98 , 99 Quantifying risk of CVEs with each TKI is challenging given the heterogeneity in data reporting from different studies and different patient populations.…”